Krystal Biotech (KRYS) Current Leases (2019 - 2026)

Krystal Biotech has reported Current Leases for 8 years, with the latest figure at $1.8 million in Q2 2026.

• Current Leases for Q2 2026 came in at $1.8 million, up 11.81% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.8 million (up 11.81% YoY), and the FY2025 annual result was $1.8 million, up 45.52% from the prior year.
• Current Leases held at $1.8 million in Q2 2026, from $1.8 million in the prior quarter.
• Over five years, Current Leases peaked at $1.8 million in Q2 2026 and troughed at $1.2 million in Q4 2024.
• A 5-year average of $1.5 million and a median of $1.5 million in 2023 frame the typical range for Current Leases.
• The widest annual swing landed in 2022, when Current Leases soared 117.75%; it then retreated 17.44% in 2024.
• A 5-year view of Current Leases shows it stood at $1.6 million in 2022, then retreated by 5.57% to $1.5 million in 2023, then retreated by 17.44% to $1.2 million in 2024, then surged by 45.52% to $1.8 million in 2025, then increased by 2.09% to $1.8 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $1.8 million in Q2 2026, $1.8 million in Q1 2026, and $1.8 million in Q4 2025.